Announcements Trials
Browse Landscape

Phase

Phase 1/2 4Phase 1 1

Status

Recruiting 2Withdrawn 1Terminated 1Active not recruiting 1

Sponsor Class

INDUSTRY 4OTHER 1

Study Type

Interventional 5

Sponsor

Cancer Type

Other solid neoplasm 5

Conditions

Advanced Solid Tumors 481Solid Tumor 418Advanced Solid Tumor 409Unspecified Adult Solid Tumor, Protocol Specific 350Solid Tumors 322Mesothelioma, Malignant 281Mesothelioma 244Solid Tumor, Adult 113Carcinoma, Non-Small-Cell Lung 109Retinoblastoma 81Ovarian Neoplasms 65Lung Neoplasms 61Melanoma 56Sarcoma 52Stomach Neoplasms 50Carcinoma, Renal Cell 49Colorectal Neoplasms 46Small Cell Lung Carcinoma 45Pancreatic Neoplasms 45Esophageal Neoplasms 45Neoplasms 43Uterine Cervical Neoplasms 41Breast Neoplasms 38Advanced or Metastatic Solid Tumors 35Hematopoietic and Lymphatic System Neoplasm 34Neoplasm Metastasis 33Squamous Cell Carcinoma of Head and Neck 32Advanced Malignant Solid Tumors 31Solid Tumours 30Triple Negative Breast Neoplasms 29

Interventions

tebentafusp 1pembrolizumab 1fludarabine 1atezolizumab 1Interleukin-2 1Drug Therapy 1Cyclophosphamide 1Bevacizumab 1Antibodies, Monoclonal 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

5 trials
RecentStart dateEnrollment
Interventional × Select Advanced Solid Tumors × Other solid neoplasm × Clear all
NCT06598371 2026-05-20

A Phase 1/2 Study of KSQ-004EX, Autologous Tumor Infiltrating Lymphocytes Engineered to Inactivate Genes Encoding SOCS1 and Regnase-1, in Patients With Select Advanced Solid Tumors

M.D. Anderson Cancer Center

Phase 1/2 Recruiting
141 enrolled
Other solid neoplasm

Select Advanced Solid Tumors

NCT04262466 2026-03-06

Safety and Efficacy of IMC-F106C as a Single Agent and in Combination With Checkpoint Inhibitors

Immunocore Ltd

Phase 1/2 Active not recruiting
410 enrolled
Other solid neoplasm

Select Advanced Solid Tumors

NCT06402201 2026-02-27

First in Human Study of CDR404 in HLA-A*02:01 Participants With MAGE-A4 Expressing Solid Tumors

CDR-Life AG

Phase 1 Recruiting
42 enrolled
Other solid neoplasm

Select Advanced Solid Tumors

NCT03973333 2024-10-18

Safety and Efficacy of IMC-C103C as Monotherapy and in Combination With Atezolizumab

Immunocore Ltd

Phase 1/2 Withdrawn
Other solid neoplasm

Select Advanced Solid Tumors

NCT03515551 2022-03-11

Safety and Efficacy of IMCnyeso in Advanced NY-ESO-1 and/or LAGE-1A Positive Cancers

Immunocore Ltd

Phase 1/2 Terminated
29 enrolled 25 charts
Other solid neoplasm

Select Advanced Solid Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡